Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

113.75 -3.02 (-2.59%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
News headline image
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' ↗
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken... 
Via Benzinga
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Ryan Richardson to Step Down from the Management Board
From BioNTech SE
Via GlobeNewswire
News headline image
Breaking Down BioNTech: 12 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
12 Analysts Have This To Say About BioNTech ↗
 
Via Benzinga
News headline image
Why Is AbbVie Stock Trading Higher On Thursday? ↗
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
News headline image
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months ↗
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute. 
Via Benzinga
Topics Intellectual Property
News headline image
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗
Via Benzinga
News headline image
Ex-Pfizer Exec Pulled Into House Probe Over Alleged COVID Vaccine Delay Through 2020 Election ↗
The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election. 
Via Stocktwits
Topics Government Law Enforcement
News headline image
Expert Outlook: BioNTech Through The Eyes Of 11 Analysts ↗
 
Via Benzinga
News headline image
5 Stocks To Ride The German Market Rally ↗
 
Via Benzinga
News headline image
Accenture To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Market Monitor News June 13 (Oracle UP - Gamestop DOWN) ↗
U.S. stocks edge higher as inflation cools, Oracle soars on AI growth, and markets brace for Israel-Iran conflict escalation. 
Via Chartmill
Topics Artificial Intelligence Economy
News headline image
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal ↗
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline. 
Via Benzinga
News headline image
BioNTech To Acquire CureVac In All-Stock Deal Valued At $1.25B: Retail Sees Breakthrough In Cancer Treatment ↗
Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares. 
Via Stocktwits
News headline image
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
From BioNTech SE
Via GlobeNewswire
News headline image
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading ↗
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks. 
Via Benzinga
News headline image
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
From FN Media Group LLC
Via GlobeNewswire
News headline image
Vaccine Stocks Alert: Has RFK Jr.'s CDC Panel Shakeup Sent Retail Traders To The Sidelines? ↗
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust." 
Via Stocktwits
Topics Government
News headline image
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr. ↗
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition. 
Via Investor's Business Daily
Topics Government
News headline image
Micron To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Market Monitor News June 03 (Cleveland-Cliffs, Blueprint Medicines UP - First Solar DOWN) ↗
Wall Street Climbs Despite Trade Tensions: Steel Stocks Shine, Apple Impresses 
Via Chartmill
News headline image
Why BioNTech Stock Soared Today ↗
Bristol Myers Squibb just agreed to shower BioNTech with cash. 
Via The Motley Fool
News headline image
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug ↗
BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion. 
Via Benzinga
News headline image
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug ↗
BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028. 
Via Stocktwits
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.